GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹1,608 Cr | ₹1,565 Cr | ₹1,398 Cr | ₹729 Cr | ₹582 Cr |
What is the latest Total Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹1,608 Cr |
| Mar2025 | ₹1,565 Cr |
| Mar2024 | ₹1,398 Cr |
| Mar2023 | ₹729 Cr |
| Mar2022 | ₹582 Cr |
How is Total Current Liabilities of GLAND PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,608 Cr | 2.78 | |
| Mar2025 | ₹1,565 Cr | 11.91 | |
| Mar2024 | ₹1,398 Cr | 91.78 | |
| Mar2023 | ₹729 Cr | 25.28 | |
| Mar2022 | ₹582 Cr | - | |
Compare Total Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹46,536.6 Cr | -3% | 18.6% | 43% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,090.0 Cr | 1% | -2.7% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹226,976.0 Cr | 0.7% | 17.1% | 40.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,639.0 Cr | -0.3% | -3.7% | 37.9% | Stock Analytics | |
| CIPLA | ₹115,216.0 Cr | -0.3% | 2.3% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.4 Cr | -1.4% | 0.7% | -6.2% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -3% |
18.6% |
43% |
| SENSEX | -0.6% |
1% |
-3.7% |
You may also like the below Video Courses